Genoway
Research Genoway (ALGEN) on Bullrun: market cap EUR 30.23M, P/E 24.5. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerALGEN
- ExchangePA
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 30.23M
- P/E24.5
- Financial periodFY2025
- RevenueEUR 20.96M
- Revenue growth-5.0%
- Net incomeEUR 927.75K
- Free cash flow-EUR 12.35M
- Gross margin48.9%
Valuation Snapshot
latest market cap is EUR 30.23M; P/E is 24.5.
Peer valuation comparison
Latest P/E is 24.5x versus a Healthcare sector median of 24.46x.
Latest P/E is 24.5x versus a France median of 15.25x (60.7% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 20.96M | EUR 927.75K | -EUR 12.35M | 48.9% | 0.08 | EUR 549.29K | EUR 13.77M | EUR 24.97M |
| FY2024 | EUR 22.06M | EUR 1.83M | EUR 2.99M | 48.4% | 0.2 | EUR 4.95M | EUR 5.58M | EUR 18.57M |
| FY2023 | EUR 20.05M | EUR 1.57M | EUR 1.28M | 52.2% | 0.19 | EUR 4.26M | EUR 7.23M | EUR 17.38M |
| FY2022 | EUR 17.05M | EUR 777.75K | EUR 438.60K | 50.9% | 0.1 | EUR 4.88M | EUR 9.05M | EUR 16.17M |
| FY2021 | EUR 14.02M | -EUR 322.60K | n/a | 41.4% | -0.04 | EUR 5.61M | EUR 10.83M | EUR 14.72M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-27 | EUR 30.23M | 24.5 | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Genoway
genOway Société anonyme, a biotechnology company, engages in the development and commercialization of custom genetically modified mouse, rat, and cell line models worldwide. It produces customized mouse models, such as knockout (KO) and knockin (KI) mouse models; customized rat models, including constitutive and conditional KO, point mutation KI, and quick KI rat models; and customized cell lines, such as constitutive and inducible KO, point mutation KI, reporter KI, quick KI, and KI cell lines.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Genoway's market cap?
Genoway's market capitalization is EUR 30.23M.
What is Genoway's P/E ratio?
Genoway's price-to-earnings (P/E) ratio is 24.5.
What does Genoway do?
genOway Société anonyme, a biotechnology company, engages in the development and commercialization of custom genetically modified mouse, rat, and cell line models worldwide. It produces customized mouse models, such as knockout (KO) and knockin (KI) mouse models; customized rat models, including constitutive and conditional KO, point mutation KI, and quick KI rat models; and customized cell lines, such as constitutive and inducible KO, point mutation KI, reporter KI, quick KI, and KI cell lines.